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alone was without effect but in combination with IFN-gamma mark-
edly impaired the ability of the long-acting beta-agonist to phospho-
rylate CREB. This suggests a novel mechanism whereby IFN-gamma 
interferes with beta-agonist signaling by impairing phosphorylation 
of CREB. This may be important in reducing the responses to beta-
agonists in refractory asthma.
Conclusion: IFN-gamma interferes with beta-2 agonist signaling 
by impairing phosphorylation of CREB. This may be important in 
reducing the responses to beta-agonists in refractory asthma.
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Introduction: Ulcerative colitis is an inflammatory chronic disease 
primarily affecting the colonic mucosa; the extent and severity of 
colon involvement are variable. The cause of UC remains unknown. 
However, some findings recently point to an overstimulation or inad-
equate regulation of the mucosal immune system as a major patho-
physiologic pathway. The role of angiotensin-converting enzyme 
blockers or angiotensin receptor blockers in the possible modulation 
of colon inflammation had not been verified. This prompted us to 
assess and compare the possible protective and therapeutic effects of 
captopril and valsartan on the extent and severity of ulcerative colitis 
induced by acetic acid in rats and to study the possible underlying 
mechanism of action of these drugs.
Patients (or Materials) and Methods: Seventy male Wistar albino 
rats were used. The animals were randomly divided into 7 groups 
each of 10 rats. Group 1: Normal control group, received Arabic 
gum PO 0.5 mlkg–1 (using gavage for all groups). Group 2: Acetic 
acid control group given 2 mL/rat 3% acetic acid rectally and Arabic 
gum PO for 2 weeks before induction of colitis. Group 3: Acetic acid 
control group 2 mL/rat 3% acetic acid rectally and Arabic gum PO 
for 2 weeks after induction of colitis. Group 4: Taken captopril HCl 
dissolved in Arabic gum at a dose of 30 mgkg-1 PO daily for 2 weeks 
before induction of ulcerative colitis. Group 5: Taken valsartan dis-
solved in Arabic gum at a dose of 30 mgkg-1 PO daily for 2 weeks 
before induction of ulcerative colitis. Group 6: Taken captopril HCl 
at a doses of 30 mgkg-1 PO once daily for 2 weeks after induction 
of UC. Group 7: Taken valsartan in a doses of 30 mgkg-1 PO once 
daily for 2 weeks after induction of ulcerative colitis.
Results: The results were assessed by histologic assessment of 
colonic tissues and measurement of malondialdehyde (MDA), tumor 
necrosis factor (TNF-α ), transforming growth factor (TGF-1b), 
angiotensin-converting enzyme (ACE), reduced glutathione (GSH), 
and platelet activating factor (PAF) levels in colonic tissues. Oral pre-
treatment with captopril or valsartan in a dose of 30 mgkg-1 body 
weight (prophylactic groups) and continuously for 2 weeks after 
induction (therapeutic groups) significantly reduce MDA, TNF-α , 
PAF, TGF-1b, and ACE levels in colonic tissues as compared with 
acetic acid control group. Also, a significant increase in GSH level 
was observed in colonic tissues. Captopril and valsartan attenu-
ated the macroscopic and microscopic colonic damage induced by 
acetic acid.
Conclusion: These results suggest that either captopril or valsar-
tan may be effective as prophylactic or treatment of UC through 
inhibition of ACE and scavenging effect on oxygen-derived free 
radicals.
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Introduction: Nonsteroidal anti-inflammatory drugs represent 1 of 
the most widely prescribed drugs used for treatment of pain and 
inflammation. The prescription of current existing anti-inflammatory 
drugs is hampered by their adverse effects over time. In the recent 
years, there is an upsurge in the areas related to newer developments 
in the prevention of disease especially the role of free radicals and 
antioxidants. Phenolic compounds are receiving increased attention 
as epidemiologic studies have highlighted the association between the 
consumption of polyphenolic–rich food and beverages and the pre-
vention of various human diseases. The present study investigated the 
analgesic and anti-inflammatory effects of chlorogenic acid (CGA), a 
polyphenolic compound present in many foods and beverages using 
carrageenan (Carr)-induced paw edema in rats and formalin – induce 
analgesia in mice.
Patients (or Materials) and Methods: Swiss mice (25–35 g) and 
Wistar rats (180–220 g), were used, chemicals and drugs (Formalin, 
Carrageenan, Indomethacin, CGA). Elisa Kits were used to study the 
effect of CGA on Carr-induced paw edema, 0.1 mL of 1% suspen-
sion of Carr in 0.9% Nacl solution was injected. The antinociceptive 
effects of CGA were tested by the formalin- induced hindpaw licking 
procedure in the day light. Elisa Kits were used to study the effects of 
CGA on some indices of oxidative stress. Reduced Glutathione and 
Malondialdehyde in paw tissues.
Results: Treatment of rats with CGA (50, 100, 150 mg/kg) signifi-
cantly reduced the rats paw edema induced by Carr and the formalin- 
induced pain in mice (P < 0.05) as compared with control groups. A 
significant reduction in rat paw volume in nitric oxide induced edema 
was observed (P < 0.05).CGA produced a significant reduction in 
malondialdehyde and significant increase in reduced glutathione in 
paw tissues (P < 0.05).
Conclusion: These results confirm that CGA has both analgesic and 
anti-inflammatory properties that may be related to the ability of 
this polyphenol to reduce the levels of superoxide and peroxynitrite 
anion radicals. CGA showed a promising potential drug of natural 
anti-inflammatory property to control oxidative stress.
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Introduction: The pharmacologic profile of antibodies to S100 pro-
tein (anti-S100) in release-active form has been studied since 1998. 
Animal studies revealed that they possess anxiolytic-like, antidepres-
sant-like, and neuroprotective activity. GABA-ergic system as well as 
sigma1 receptor are involved in the realization of their effects. The 
aim of the present study is to assess the influence of anti-S100 treat-
ment on the course of experimental allergic encephalomyelitis (EAE).
Patients (or Materials) and Methods: EAE was induced female 
Wistar rats (200–220 g) by a single subcutaneous inoculation of a 
spinal cord homogenate emulsified in complete Freund’s adjuvant 
(100 mg of homogenate of homologous spinal cord, 0.2 mL CFA, 
